Schedule 13G ownership disclosure
4D Molecular Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 35104E100
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- THE GOLDMAN SACHS GROUP, INC.
Shares: 4,423,435.48 · Class: 9.6%
- GOLDMAN SACHS & CO. LLC
Shares: 4,423,435.48 · Class: 9.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000769993-25-000070
- Form type
- SCHEDULE 13G/A
- Filer
- 4D Molecular Therapeutics, Inc.
- CIK
- CIK 1650648
- Filed
- Feb 10, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership